See more : Nocturne Acquisition Corporation (MBTCR) Income Statement Analysis – Financial Results
Complete financial analysis of Oncotelic Therapeutics, Inc. (OTLC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncotelic Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Equital Ltd. (EQTL.TA) Income Statement Analysis – Financial Results
- Lotte Non – Life Insurance Co., Ltd. (000400.KS) Income Statement Analysis – Financial Results
- CrossFirst Bankshares, Inc. (CFB) Income Statement Analysis – Financial Results
- Sartorius Aktiengesellschaft (SUVPF) Income Statement Analysis – Financial Results
- Express, Inc. (EXPR) Income Statement Analysis – Financial Results
Oncotelic Therapeutics, Inc. (OTLC)
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.00K | 0.00 | 0.00 | 1.74M | 0.00 | -100.00 | -100.00 | 0.00 | 0.00 | 95.00K | 95.00K | 156.00K | 0.00 | 0.00 | 0.00 | 12.00K | 12.00K | 0.00 | 1.00K | 7.00K | 30.00K | 334.52K | 9.86M | 1.69M | 1.27M | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K | 100.00K | 100.00K |
| Cost of Revenue | 0.00 | 12.84K | 61.51K | 0.00 | 60.60K | 34.19K | 9.00K | 19.00K | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.94M | 22.27M | 17.92M | 13.05M | 10.48M | 0.00 | 0.00 | 1.51M | 1.61M | 1.26M | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 70.00K | -12.84K | -61.51K | 1.74M | -60.60K | -34.29K | -9.10K | -19.00K | -20.00K | 95.00K | 95.00K | 156.00K | 0.00 | 0.00 | 0.00 | -25.93M | -22.26M | -17.92M | -13.05M | -10.47M | 30.00K | 334.52K | 8.35M | 79.97K | 16.27K | 200.00K | 100.00K | 100.00K | 100.00K | 300.00K | 100.00K | 100.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 34,289.00% | 9,100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | -216,066.67% | -185,508.33% | 0.00% | -1,304,700.00% | -149,614.29% | 100.00% | 100.00% | 84.70% | 4.72% | 1.28% | 200.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 61.14K | 756.91K | 3.66M | 4.30M | 1.37M | 815.00K | 10.47M | 8.76M | 9.09M | 7.41M | 3.64M | 3.52M | 5.29M | 12.11M | 22.26M | 18.43M | 14.13M | 10.82M | 7.10M | 5.85M | 3.94M | 5.10M | 6.13M | 8.06M | 8.40M | 10.40M | 7.30M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 573.73K | 4.85M | 5.47M | 5.02M | 2.94M | 2.19M | 3.37M | 5.00M | 4.60M | 5.24M | 4.74M | 4.69M | 5.38M | 5.89M | 8.90M | 7.52M | 8.16M | 7.10M | 5.95M | 4.54M | 5.28M | 7.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.43B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 573.73K | 4.85M | 5.47M | 5.02M | 2.94M | 2.19M | 3.37M | 5.00M | 4.60M | 5.24M | 4.74M | 4.69M | 5.38M | 5.89M | 8.90M | 7.52M | 8.16M | 7.10M | 5.95M | 4.54M | 5.28M | 7.44M | 5.45M | 3.16M | 3.34M | 3.10M | 3.00M | 1.80M | 4.10M | 3.10M | 2.10M | 1.60M |
| Other Expenses | 6.08M | 533.49K | 0.00 | 0.00 | 0.00 | -1.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 98.00K | 98.00K | 97.54K | 297.54K | -230.83K | 35.00K | 100.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.72M | 5.61M | 9.13M | 9.33M | 4.31M | 3.00M | 13.84M | 13.76M | 13.68M | 12.65M | 8.38M | 8.21M | 10.67M | 18.00M | 31.16M | 25.95M | 22.29M | 17.92M | 13.05M | 10.49M | 9.32M | 12.64M | 11.88M | 10.99M | 11.77M | 13.60M | 10.40M | 6.60M | 4.10M | 3.10M | 2.10M | 1.60M |
| Cost & Expenses | 6.72M | 5.61M | 9.13M | 9.33M | 4.31M | 3.00M | 13.84M | 13.76M | 13.68M | 12.65M | 8.38M | 8.21M | 10.67M | 18.00M | 31.16M | 25.95M | 22.29M | 17.92M | 13.05M | 10.49M | 9.32M | 12.64M | 13.39M | 12.60M | 13.02M | 13.50M | 10.40M | 6.60M | 4.10M | 3.10M | 2.10M | 1.60M |
| Interest Income | 0.00 | 2.97K | 2.00K | 2.00K | 123.00 | 16.00K | 35.00K | 106.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 618.00K | 1.96M | 0.00 | 0.00 | 0.00 | 0.00 | 334.52K | 906.89K | 1.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.04M | 2.97M | 2.00M | 2.00M | 749.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K | 52.72K | 61.25K | 102.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -513.26K | 12.84K | 61.51K | 364.21K | 60.60K | 34.19K | 9.00K | 19.00K | 20.00K | 109.00K | 110.00K | 127.00K | 150.00K | 96.00K | 123.00K | 231.00K | 213.00K | 186.00K | 142.00K | 125.00K | 576.00K | 243.11K | -7.13M | -230.83K | 35.00K | 100.00K | 100.00K | 500.00K | 300.00K | 0.00 | 0.00 | -100.00K |
| EBITDA | -7.16M | -5.60M | -9.06M | -7.61M | -4.25M | -678.55K | -13.80M | -13.64M | -13.63M | -12.54M | -8.17M | -7.95M | -9.50M | -23.58M | -28.72M | -21.69M | -20.18M | -15.27M | -11.77M | -9.90M | -8.71M | -12.06M | -3.23M | -11.14M | -11.72M | -13.43M | -10.25M | -6.50M | -4.00M | -2.80M | -2.00M | -1.50M |
| EBITDA Ratio | -10,230.39% | 0.00% | 0.00% | -414.77% | 0.00% | 3,250,000.00% | 13,833,000.00% | 0.00% | 0.00% | -13,318.95% | -8,718.95% | -5,150.64% | 0.00% | 0.00% | 0.00% | -242,583.33% | -183,241.67% | 0.00% | -1,404,500.00% | -154,442.86% | -32,226.67% | -4,007.35% | -27.13% | -657.14% | -921.28% | -15,300.00% | -12,400.00% | -7,200.00% | -4,400.00% | -933.33% | -2,000.00% | -1,500.00% |
| Operating Income | -6.65M | -9.72M | -9.13M | -7.58M | -4.31M | -3.00M | -13.84M | -13.76M | -13.68M | -12.65M | -8.28M | -8.07M | -11.89M | -18.51M | -31.16M | -25.94M | -22.27M | -17.92M | -13.05M | -10.48M | -9.29M | -12.30M | -3.53M | -10.91M | -11.75M | -13.40M | -10.30M | -6.50M | -4.00M | -2.80M | -2.00M | -1.50M |
| Operating Income Ratio | -9,497.16% | 0.00% | 0.00% | -435.69% | 0.00% | 3,002,000.00% | 13,842,000.00% | 0.00% | 0.00% | -13,315.79% | -8,715.79% | -5,174.36% | 0.00% | 0.00% | 0.00% | -216,166.67% | -185,608.33% | 0.00% | -1,304,800.00% | -149,714.29% | -30,960.00% | -3,678.28% | -35.75% | -643.52% | -924.04% | -13,400.00% | -10,300.00% | -6,500.00% | -4,000.00% | -933.33% | -2,000.00% | -1,500.00% |
| Total Other Income/Expenses | -1.56M | 14.40M | -1.39M | -2.39M | -2.33M | 0.00 | 30.00K | 105.00K | 28.00K | 3.00K | 3.00K | -7.00K | 2.24M | -5.26M | 2.21M | 4.02M | 1.88M | 1.98M | 1.14M | 456.00K | 920.00K | 0.00 | -552.31K | 0.00 | 0.00 | 2.09M | 2.23M | 700.00K | 400.00K | 2.80M | 2.00M | 0.00 |
| Income Before Tax | -8.21M | 4.68M | -10.52M | -9.97M | -6.64M | -2.74M | -13.81M | -13.65M | -13.65M | -12.65M | -8.28M | -8.08M | -10.88M | -24.28M | -28.94M | -22.54M | -22.34M | -15.46M | -11.91M | -10.02M | -8.33M | -10.96M | -4.08M | 0.00 | 0.00 | -11.40M | -8.10M | -5.80M | -3.60M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -11,722.95% | 0.00% | 0.00% | -572.81% | 0.00% | 2,737,000.00% | 13,812,000.00% | 0.00% | 0.00% | -13,312.63% | -8,712.63% | -5,178.85% | 0.00% | 0.00% | 0.00% | -187,825.00% | -186,200.00% | 0.00% | -1,190,900.00% | -143,200.00% | -27,773.33% | -3,276.54% | -41.35% | 0.00% | 0.00% | -11,400.00% | -8,100.00% | -5,800.00% | -3,600.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -13.14M | 876.57K | 1.53M | 749.60K | -265.00K | -30.00K | -105.00K | -28.00K | -3.00K | -3.00K | 22.00K | -2.24M | 5.26M | -6.43M | -4.54M | -1.88M | -2.46M | -1.14M | -456.00K | -920.00K | -1.29M | 613.56K | -1.82M | -1.30M | -1.90M | -2.20M | -500.00K | -300.00K | 2.80M | 2.00M | 100.00K |
| Net Income | -7.90M | 17.82M | -11.39M | -11.50M | -7.39M | -2.74M | -13.81M | -13.65M | -13.65M | -12.65M | -8.28M | -8.08M | -9.65M | -23.77M | -24.73M | -21.40M | -20.39M | -15.46M | -11.91M | -10.02M | -8.37M | -11.01M | -4.14M | -9.09M | -10.45M | -11.50M | -8.10M | -6.00M | -3.70M | -2.80M | -2.00M | -1.60M |
| Net Income Ratio | -11,290.13% | 0.00% | 0.00% | -660.65% | 0.00% | 2,737,000.00% | 13,812,000.00% | 0.00% | 0.00% | -13,312.63% | -8,712.63% | -5,178.85% | 0.00% | 0.00% | 0.00% | -178,341.67% | -169,908.33% | 0.00% | -1,190,900.00% | -143,200.00% | -27,893.33% | -3,292.30% | -41.97% | -536.15% | -821.50% | -11,500.00% | -8,100.00% | -6,000.00% | -3,700.00% | -933.33% | -2,000.00% | -1,600.00% |
| EPS | -0.02 | 0.05 | -0.04 | -0.13 | -0.12 | -0.07 | -0.52 | -0.51 | -0.54 | -0.75 | -2.95 | -5.48 | -10.37 | -71.60 | -111.11 | -167.56 | -175.20 | -134.28 | -145.35 | -145.28 | -152.33 | -211.22 | -88.04 | -195.06 | -244.09 | -271.28 | -198.94 | -193.56 | -151.20 | -134.40 | -120.00 | -108.00 |
| EPS Diluted | -0.02 | 0.04 | -0.04 | -0.13 | -0.12 | -0.07 | -0.52 | -0.51 | -0.54 | -0.75 | -2.95 | -5.48 | -10.37 | -71.60 | -111.11 | -167.56 | -175.20 | -134.28 | -145.35 | -145.28 | -152.33 | -211.22 | -88.04 | -195.06 | -244.09 | -271.28 | -198.94 | -193.56 | -151.20 | -134.40 | -120.00 | -108.00 |
| Weighted Avg Shares Out | 396.17M | 384.08M | 303.08M | 88.10M | 59.96M | 37.25M | 26.55M | 26.55M | 25.20M | 16.97M | 2.80M | 1.47M | 931.00K | 332.00K | 222.56K | 127.72K | 116.38K | 115.11K | 81.93K | 69.00K | 54.93K | 52.14K | 47.01K | 46.59K | 42.81K | 42.39K | 40.72K | 31.00K | 24.47K | 20.83K | 16.67K | 14.82K |
| Weighted Avg Shares Out (Dil) | 396.17M | 457.30M | 303.08M | 88.10M | 59.96M | 37.25M | 26.55M | 26.55M | 25.20M | 16.97M | 2.80M | 1.47M | 931.00K | 332.00K | 222.56K | 127.72K | 116.38K | 115.11K | 81.93K | 69.00K | 54.93K | 52.14K | 47.01K | 46.59K | 42.81K | 42.39K | 40.72K | 31.00K | 24.47K | 20.83K | 16.67K | 14.82K |
ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024
AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go...
Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence
AGOURA HILLS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that Product Manager Scott Myers, working through GMP Biotechnology Limited, our 45% Joint Venture with Dragon Capital Limited,...
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science & Technology (IDDST) (Europe), June 17-19, 2024 at...
ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego. The BIO International Convention is the largest...
ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING
AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting.
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
- The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy combinations HUNTINGTON BEACH, CA / ACCESSWIRE / April 29, 2024 / Mosaic ImmunoEngineering,...
Linkage of Cancer and Lupus in Gliomas Patients
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5)...
Invitation to Participate in STOP-PC Clinical Trial
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional information can be obtained at www.stop-pc.com. An explainer video is available at https://www.youtube.com/watch?v=C4ZsE3fulIU.
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
AGOURA HILLS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME)...
Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant
AGOURA HILLS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), unveils a state-of-the-art GMP Manufacturing Plant, a significant stride in biopharmaceutical innovation, through its joint venture Sapu Biosciences LLC. Situated...
Source: https://incomestatements.info
Category: Stock Reports